Table 1. Demographics and main clinical and pathological features of the analyzed series.
| Parameters | Retrospective series | |
|---|---|---|
| n | % | |
| PSA | ||
| <10ng/ml | 109 | 55.8 |
| 10–20ng/ml | 54 | 27.7 |
| >20ng/ml | 32 | 16.5 |
| Gleason-sp | ||
| ≤6 | 66 | 33.8 |
| 7 | 106 | 54.4 |
| 8–10 | 23 | 11.8 |
| cT | ||
| <cT2b | 177 | 90.8 |
| cT2b | 18 | 9.2 |
| pT | ||
| <pT2 | 91 | 46.7 |
| ≥pT3 | 104 | 53.3 |
| pN * | ||
| pN0 | 169 | 93.9 |
| pN≥1 | 11 | 6.1 |
SP, specimen; cT, clinical stage; pT, pathological stage; PSA, prostatic specific antigen; pN, pathologic stage with respect to lymph node status; NA, not available.
* Lymphadenectomy was limited to the obturator fossa in most of the cases at the inclusion period.